ClinicalTrials.gg
RecruitingNCT06409013Updated Aug 4, 2026

Evaluation of Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography in Patients With Sarcoma

An observational study in Bone Sarcoma and Soft Tissue Sarcoma, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Mayo Clinic · Observational

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
75
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluates the effectiveness of intraoperative indocyanine green dye and fluoroscopic technology in confirming negative margins after tumor removal.

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate the use of indocyanine green (ICG) as an intraoperative guide during bone and soft tissue sarcoma resection.

OUTLINE: This is an observational study.

Patients receive ICG infusion prior to undergoing scheduled resection and have medical records reviewed on study.

02

Conditions studied

  • Bone Sarcoma
  • Soft Tissue Sarcoma
03

In context

Bone Neoplasms

258 studies on the registry are indexed under Bone Neoplasms; 68 are open to participants now.

This study's planned enrollment of 75 is below the median of 101 across 82 observational studies indexed under Bone Neoplasms.

Browse Bone Neoplasms studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,269 studies on the registry; 672 are open to participants now.

Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with biopsy-proven bone or soft tissue sarcoma undergoing resection recruited through Mayo Clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with -proven bone or soft tissue sarcoma undergoing resection

Exclusion criteria

Exclusion Criteria:

  • Chronic kidney disease
  • Anaphylaxis to dyes
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
75 participants (estimated)

Groups and cohorts

  • Observational

    Patients receive ICG infusion prior to undergoing scheduled resection and have medical records reviewed on study.

    Other: Non-Interventional Study

Interventions

  • OtherNon-Interventional Study

    Non-interventional study

06

What researchers measure

Primary outcomes

  1. Accuracy of intraoperative ICG fluorescence compared to final pathology results

    Intraoperative ICG fluorescence and deduced margins will be analyzed and compared the accuracy to final pathology margins. Negative predictive value will be calculated.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06409013
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
May 10, 2024
Start date
Mar 14, 2024
Primary completion
Mar 30, 2027 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Aug 4, 2026

Study contacts

Clinical Trials Referral Office
Contact
mayocliniccancerstudies@mayo.edu
855-776-0015
Laura Dohrmann
Contact
Beinborn.Laura@mayo.edu
507-266-5886
Matthew T. Houdek, M.D.
principal investigator · Mayo Clinic in Rochester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion